ENERGY BALANCE IN PROSTATE CANCER
前列腺癌的能量平衡
基本信息
- 批准号:3201786
- 负责人:
- 金额:$ 15.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1992
- 资助国家:美国
- 起止时间:1992-09-25 至 1995-08-31
- 项目状态:已结题
- 来源:
- 关键词:adenosine triphosphate antineoplastics athymic mouse bioenergetics calcium flux cell cycle cellular respiration clinical trials clone cells combination cancer therapy drug resistance drug screening /evaluation electron microscopy glycolysis human subject human therapy evaluation mitochondria neoplasm /cancer chemotherapy phosphatidylinositols phospholipase C prostate neoplasms suramin
项目摘要
Prostate cancer accounts for 122,000 new cases and 30,000 cancer-related
deaths in the United States each year. Although hormone therapy is
effective in approximately 70% of the men with metastatic cancer,
ultimately they all suffer progressive disease with androgen-independent
prostate cancer. No effective therapy exists for androgen-independent
prostate cancer.
The antiparasitic drug, suramin, has antiproliferative effects in human
carcinoma cells. Most recently, suramin has demonstrated activity in
patients with prostate cancer. We have developed evidence that suramin
rapidly inhibits cellular respiration and disrupts cellular energy
balance in intact prostate cancer cells. Disruption of energy balance or
respiration represents a possible antiproliferative mechanism in cancer
cells, as is felt to be a primary mechanism for suramin's action in
parasitic diseases. This proposed mechanism of action for suramin can
explain the most prominently observed clinical toxicities of
nephrotoxicity, adrenal toxicity, coagulopathy and demyelinating
neuropathy.
This proposal outlines our plan to use suramin as a model to target
cellular energy metabolism in antineoplastic therapy. we have outlined an
experimental plan to further delineate suramin's mechanism of action and
use of this knowledge to search for other drugs synergistic to suramin.
Finally, we plan to utilize our Phase I drug development program to apply
this knowledge in clinical settings, starting with our ongoing Phase I
trial of suramin.
前列腺癌占122,000例新病例和30,000例癌症相关病例
美国每年的死亡人数。 虽然激素治疗是
对大约70%的转移性癌症患者有效,
最终他们都患有进行性疾病,
前列腺癌 对于雄激素非依赖性
前列腺癌
抗寄生虫药苏拉明在人体内具有抗增殖作用,
癌细胞 最近,苏拉明已被证明在
前列腺癌患者。 我们有证据表明苏拉明
迅速抑制细胞呼吸并破坏细胞能量
在完整的前列腺癌细胞中保持平衡。 破坏能量平衡或
呼吸是癌症中一种可能的抗增殖机制
细胞,因为被认为是苏拉明的行动,
寄生虫病 苏拉明的这种作用机制可以
解释了最显著的临床毒性
肾毒性、肾上腺毒性、凝血病和脱髓鞘
神经病变
该提案概述了我们的计划,以苏拉明为模型,
细胞能量代谢的影响。我们概述了一个
进一步阐明苏拉明作用机制的实验计划,
利用这一知识寻找与苏拉明协同作用的其他药物。
最后,我们计划利用我们的I期药物开发计划,
从我们正在进行的第一阶段开始,
苏拉明的审判
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE WILDING其他文献
GEORGE WILDING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE WILDING', 18)}}的其他基金
Validation of Biomarkers to Distinguish Aggressive from Indolent Prostate Cancer
验证区分侵袭性前列腺癌和惰性前列腺癌的生物标志物
- 批准号:
8489433 - 财政年份:2013
- 资助金额:
$ 15.18万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 15.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 15.18万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 15.18万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 15.18万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 15.18万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 15.18万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 15.18万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 15.18万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 15.18万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 15.18万 - 项目类别: